The IQVIA Institute for Human Data Science

Evidence-based insights for healthcare

The IQVIA Institute for Human Data Science contributes to the advancement of human health globally through timely research, insightful analysis and scientific expertise applied to granular non-identified patient-level data.
Subscribe to the IQVIA Institute
Be among the first to hear about research and activities

Latest Reports

Download the latest Institute reports

Institute Report

HIV Spending Trends

Over four decades of innovation have transformed HIV into a manageable chronic condition through advances in ART and PrEP. Yet unmet needs persist, particularly for vulnerable populations, as drug resistance and funding challenges emerge. This IQVIA Institute report examines global HIV R&D trends, spending dynamics, and policy pressures, highlighting the need for sustained investment and collaboration to ensure continued innovation and equitable access to care.

Institute Report

Expanding Options for Emerging Biopharma in the U.S.: A Decade of Change

Over the past decade, emerging biopharma (EBP) companies have transformed the innovation landscape - originating nearly half of all new drug launches and driving advances in specialty, orphan, and first-in-class therapies. This IQVIA Institute report analyzes how EBPs are reshaping R&D productivity, funding models, and commercialization in the U.S. market, offering insights into their expanding role in delivering breakthrough treatments.

Institute Report

Drug Expenditure Dynamics 2000–2022

This report examines global trends in medicine spending across 12 major markets, revealing that drug costs have remained a stable share – around 15% of total healthcare expenditure for over two decades. The report provides a clearer view of total drug spending by incorporating both retail and hospital use, offering vital context for policymakers evaluating healthcare efficiency and cost containment.

Webinar

Strengthening Europe as a Global Center for Oncology Trials: Pre-ESMO Symposium 2025

Efforts to strengthen Europe as a global center for oncology clinical trials have been underway for some time, and multiple initiatives have been launched by stakeholders in recent years.  At the same time, changes at the U.S. FDA and implementation of the EU Health Technology Assessment Regulation from January 2025 are bringing new considerations for sponsors deciding where to place their trial sites.

During this symposium, we will assess what progress has been achieved since the IQVIA Institute’s symposium held a year ago, examine the changes brought by the new U.S. administration, and discuss the impact of Joint Clinical Assessment requirements for all new oncology drugs submitted for registration by the EMA. We will also explore the increased use of trial sites in China and Australia.

Institute Report

Advancing Evidence-Based Academic Research 2025

Bibliography of Published Papers and Presentations Using IQVIA Information

View all of the IQVIA Institute's Upcoming and On-Demand Events

Trending

Annual Reports on Latest Trends

The Global Use of Medicines

Learn about spending and usage of medicines in the past year and outlook to the future, globally and across specific therapy areas and countries.

Global Trends in R&D

Discover trends in drug approvals and launches, pipeline activity, and data on clinical trial activity.

The Use of Medicines in the U.S.

Examine the state of the U.S. health system, medicine usage, drug pricing, and costs for patients.

Global Oncology Trends

Explore research and development in oncology and the progress being made to improve representativeness of race and ethnicity in clinical trial populations.

Contact Us